Paul Hastings LLP advised Leerink Partners and Stifel as joint bookrunning managers in the offering. Evolus, Inc. (Nasdaq: EOLS) announced the pricing of its underwritten offering...
Evolus’ $50.0 Million Common Stock Offering
Humacyte’s $40 Million Public Offering
Covington & Burling represented Humacyte, while Paul Hastings advised TD Cowen, Cantor and BTIG in the offering. Humacyte, Inc. executed an underwritten public offering of 13,400,000 shares...
PepGen’s $80.1 Million Offering
Paul Hastings LLP advised Leerink Partners on the matter. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the...
Esperion Therapeutics’ $85.1 Million Public Offering
Paul Hastings LLP advised Jefferies LLC as sole book running manager in connection with Esperion Therapeutics, Inc.’s offering. Esperion Therapeutics, Inc. announced the pricing of its...